Anna Efthymiou

Anna Efthymiou

Auto-generated profile, based on publicly available information

Anna Efthymiou

Department of Hemato-Oncology, HFR Hôpital Fribourgeois, Fribourg, Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JJJeroen JWM Janssen
Jeroen JWM Janssen
BLBob Löwenberg
Bob Löwenberg
MMMarkus Manz
Markus Manz
MBMario Bargetzi
Mario Bargetzi
BBBart Biemond
Bart Biemond
GOGert Ossenkoppele
Gert Ossenkoppele
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66–81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (n = 116), days 1–21. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60–77%) vs 64% (55–73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively (p = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation was more common in the tosedostat arm as well. The results of the present study show that the addition of tosedostat to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients.

1 March 2024 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
LWLouis Wolff
Louis Wolff
LCLeo Caratsch
Leo Caratsch
FLFabian Lötscher
Fabian Lötscher
LSLuca Seitz
Luca Seitz
PSPascal Seitz
Pascal Seitz
Denis ComteDenis Comte
Denis Comte
STUDY AIMS: VEXAS syndrome is a recently discovered monogenic auto-inflammatory disease caused by a somatic mutation in the UBA1 gene that manifests with rheumatologic and haematologic features. In this report, we present the first Swiss cohort, detailing its manifestations and treatment outcomes among Swiss patients. METHODS: Data were retrospectively collected from nine hospitals across Switzerland, representing a broad geographic distribution. Treating physicians completed a standardised case report form for each patient. The principal investigator and the co-investigators collected and analysed all case report forms. RESULTS: We identified 23 patients between July 2022 and 2023, of which 17 are described. All were male. They presented with skin manifestations (88%), general symptoms (82%), venous thromboembolism (59%), ocular manifestation (59%), lung infiltrates (59%) and articular manifestations (47%). Central nervous system and kidney manifestations were very rare, and heart and digestive manifestations were absent. Macrocytic anaemia was present in all patients throughout the disease progression but only in two-thirds of patients (12/17, 71%) at the time of diagnosis. Clinical response was reached in all cases treated with ruxolitinib (4/4, 100%), upadacitinib (1/1, 100%), azacytidine (5/5, 100%) and haematopoietic stem cell transplantation (2/2, 100%). All deaths were attributed to infections (5/5, 100%). CONCLUSION: This study corroborates the clinical spectrum of VEXAS syndrome described in other cohorts. It suggests that VEXAS syndrome is not limited to patients with macrocytic anaemia. In this study, azacytidine has been used effectively among patients with myelodysplastic syndrome. In addition, Janus kinase (JAK) inhibitors, particularly ruxolitinib, have been successfully used even in those without myelodysplastic syndrome. We report two successful treatments by haematopoietic stem cell transplantation.

14 August 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Loizos PetrikkosLoizos Petrikkos
Loizos Petrikkos
MKMarie-Christine Kyrtsonis
Marie-Christine Kyrtsonis
MRMaria Roumelioti
Maria Roumelioti
GGGeorge Georgiou
George Georgiou
AEAnna Efthymiou
Anna Efthymiou
PPPanayiotis Panayiotidis
Panayiotis Panayiotidis
We performedIGHclonotypic sequence analysis in WM in order to determine whether a preferentialIGHgene rearrangement was observed and to assessIGHVmutational status in blood and/or bone marrow samples from 36 WM patients. In addition we investigated the presence ofMYD88L265P somatic mutation. AfterIGHVDJ locus amplification, monoclonal VDJ rearranged fragments were sequenced and analyzed.MYD88L265P mutation was detected by AS-PCR. The most frequent family usage wasIGHV3(74%);IGHV3-23andIGHV3-74segments were used in 26% and 17%, respectively. Somatic hypermutation was seen in 91% of cases.MYD88L265P mutation was found in 65,5% of patients and absent in the 3 unmutated. These findings did not correlate with clinical findings and outcome. Conclusion.IGH genes’repertoire differed in WM from those observed in other B-cell disorders with a recurrentIGHV3-23andIGHV3-74usage; monoclonalIGHVwas mutated in most cases, and a high but not omnipresent prevalence ofMYD88L265P mutation was observed. In addition, the identification of 3 patients with unmutatedIGHVgene segments, negative for theMYD88L265P mutation, could support the hypothesis that an extra-germinal B-cell may represent the originating malignant cell in this minority of WM patients.

1 January 2023 in Revue Medicale Suisse
Verified
Journal Article
Closed access
MPMarco Paoletti
Marco Paoletti
MAMehdi Ahmad Azizi
Mehdi Ahmad Azizi
AEAnna Efthymiou
Anna Efthymiou
Les patients avec un cancer ont un risque thrombotique artériel et veineux accru. En cas de thrombocytopénie et traitement anticoagulant (ou antiagrégan...